9 Results

People

  1. Kris
    Kris
  2. Riely
    Riely
  3. Scher
    Scher
  4. Bergagnini
    Bergagnini
  5. Chaft
    Chaft
  6. Chapman
    Chapman
  7. Hellmann
    Hellmann
  8. Ilson
    Ilson
  9. Motzer
    Motzer
  10. Rusch
    Rusch

Groups

  1. Department of Medicine (9)
  2. Solid Tumor Oncology Division (9)
  3. Thoracic Oncology (4)
  4. Genitourinary Oncology Service (3)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (1)
  6. Gastrointestinal Oncology Service (1)
  7. Melanoma and Immunotherapeutics Service (1)
  8. Surgery (1)
  1. "Journal article"
  2. "Elsevier Science, Inc."
  3. "2014"
  4. "Lancet Oncology"
  5. "Solid Tumor Oncology Division"
Formats
  1. Journal Article (9)
Groups
  1. Department of Medicine (9)
  2. Solid Tumor Oncology Division (9)
  3. Thoracic Oncology (4)
  4. Genitourinary Oncology Service (3)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (1)
  6. Gastrointestinal Oncology Service (1)

More Groups

People
  1. Gregory Riely (2)
  2. Howard Scher (2)
  3. Mark Kris (2)
  4. David Ilson (1)
  5. Isabella Bergagnini (1)
  6. Jamie Chaft (1)

More People

Years
  1. 2014 (9)
Publications
  1. Lancet Oncology (9)
Publishers
  1. Elsevier Science, Inc. (9)

Results (9)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: A multicentre, open-label, phase 2 trial
    Journal Article

    Jänne, P. A.; Ou, S. H. I.; Kim, D. W.; Oxnard, G. R.; Martins, R.; Kris, M. G.; Dunphy, F.; Nishio, M.; O'Connell, J.; Paweletz, C.; more...
    Lancet Oncology (2014)

    Fulltext@MSK | Save
  • Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): Results from the dose-finding portion of a phase 1/2 study
    Journal Article

    Gadgeel, S. M.; Gandhi, L.; Riely, G. J.; Chiappori, A. A.; West, H. L.; Azada, M. C.; Morcos, P. N.; Lee, R. M.; Garcia, L.; Yu, L.; more...
    Lancet Oncology (2014)

    Fulltext@MSK | Save
  • Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: Results from the randomised, phase 3 AFFIRM trial
    Journal Article

    Fizazi, K.; Scher, H. I.; Miller, K.; Basch, E.; Sternberg, C. N.; Cella, D.; Forer, D.; Hirmand, M.; de Bono, J. S.
    Lancet Oncology (2014)

    Fulltext@MSK | Save
  • Adjuvant treatment for gastric cancer: Too much is not enough
    Journal Article

    Ilson, D. H.
    Lancet Oncology (2014)

    Fulltext@MSK | Save
  • Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial
    Journal Article

    Kwon, E. D.; Drake, C. G.; Scher, H. I.; Fizazi, K.; Bossi, A.; Van Den Eertwegh, A. J. M.; Krainer, M.; Houede, N.; Santos, R.; Mahammedi, H.; more...
    Lancet Oncology (2014)

    Fulltext@MSK | Save
  • Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: An open-label, randomised phase 3 trial
    Journal Article

    Motzer, R. J.; Porta, C.; Vogelzang, N. J.; Sternberg, C. N.; Szczylik, C.; Zolnierek, J.; Kollmannsberger, C.; Rha, S. Y.; Bjarnason, G. A.; Melichar, B.; more...
    Lancet Oncology (2014)

    Fulltext@MSK | Save
  • Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): Extended follow-up of a phase 3, randomised, open-label study
    Journal Article

    McArthur, G. A.; Chapman, P. B.; Robert, C.; Larkin, J.; Haanen, J. B.; Dummer, R.; Ribas, A.; Hogg, D.; Hamid, O.; Ascierto, P. A.; more...
    Lancet Oncology (2014)

    Fulltext@MSK | Save
  • Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: A multicentre, open-label, phase 2 trial
    Journal Article

    Rajan, A.; Carter, C. A.; Berman, A.; Cao, L.; Kelly, R. J.; Thomas, A.; Khozin, S.; Chavez, A. L.; Bergagnini, I.; Scepura, B.; more...
    Lancet Oncology (2014)

    Fulltext@MSK | Save
  • Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: Proposal for the use of major pathological response as a surrogate endpoint
    Journal Article

    Hellmann, M. D.; Chaft, J. E.; William, W. N.; Rusch, V.; Pisters, K. M. W.; Kalhor, N.; Pataer, A.; Travis, W. D.; Swisher, S. G.; Kris, M. G.
    Lancet Oncology (2014)

    Fulltext@MSK | Save